When Direct Compression Fails at Ambient Moisture Above 45% RH

Yinhuang Extract Oral Solution Veterinary Grade API is commonly received as a concentrated liquid with total solids in the range of 20–30% w/w. If tablet manufacture is transferred to a solid-dose facility, the liquid concentrate is first spray-dried onto a carrier such as microcrystalline cellulose PH102 or maltodextrin. Direct compression of the resulting powder is rarely robust above 45% RH because the extract solids absorb surface moisture, reduce interparticulate friction, and cause punch sticking on rotary presses. A fluid-bed pre-drying step at inlet air temperature of 55–60°C until loss on drying reaches 2–4% is therefore specified before compression. Batch-to-batch variation in total solids should be measured by moisture balance and the carrier ratio adjusted accordingly. If ethanol is used in wet granulation rather than water, residual ethanol must be controlled per VICH GL18.

Wet granulation is the preferred route when the extract is available as a liquid. The granulating fluid is prepared by diluting the oral solution 1:1 with purified water. The dry mix is composed of 20–35 wt% dried extract solids, 30–45 wt% microcrystalline cellulose PH102, 10–25 wt% lactose monohydrate, 2–5 wt% crospovidone, and 0.5–1.0 wt% magnesium stearate. Granulation is performed in a high-shear mixer at impeller speed 250 rpm and chopper speed 1500 rpm until the granule D50 reaches 150–250 µm. The granules are dried at 50°C to residual moisture 2–4%, then milled through a 0.8 mm screen. Published data for this specific botanical matrix are limited, so the granulation endpoint should be confirmed by sieve analysis and tap density rather than torque only.

Tablets are compressed to hardness 60–100 N, friability not more than 1.0% per USP <1216>, and disintegration not more than 15 min in water at 37°C per USP <701>. A hydroxypropyl methylcellulose film coating of 2–3% weight gain is applied to reduce moisture ingress. The terminal veterinary tablet is typically 300 mg total mass, with the baicalin marker content set by the approved monograph rather than by fixed tablet weight. Tablets should be packaged in aluminium blister with desiccant if storage humidity exceeds 60% RH. When press speed exceeds 40 rpm on a 16-station rotary machine and ambient humidity is above 45% RH, ejection force rises and picking on upper punches becomes recurrent.

What Limits Sterile Filtration Throughput in Injection-Grade Batches?

The oral solution grade cannot be assumed to be injectable until polysaccharide, protein and endotoxin burdens are evaluated. The liquid concentrate is diluted with water for injection to 10–20% v/v, and the pH is adjusted to 5.5–6.5 with 0.1 M sodium hydroxide or hydrochloric acid. At pH values below 4.0, flavonoid aglycones precipitate as fine particulates, while above 7.5 oxidative darkening accelerates. A cold hold at 2–8°C for 12–24 h precipitates pectin-like polysaccharides. The cold suspension is then clarified by centrifugation at 4000×g for 15 min or by passage through a 0.45 µm depth filter. The clarified liquid must be retested for pH and marker assay because the cold step can reduce baicalin recovery by 2–5%.

Sterile filtration is the critical throughput bottleneck. Membrane fouling is dominated by residual phenolic-protein complexes and oligosaccharides. A 0.45 µm polypropylene prefilter connected in series with a 0.22 µm polyvinylidene difluoride membrane provides the most robust starting configuration in development trials. Differential pressure should be controlled at 0.5–0.8 bar; exceeding 1.0 bar can collapse the fouling layer and release retained particulates into the filtrate. Representative filtration development data are summarized below; they are not release specifications and must be confirmed on each batch.

After filtration, tonicity is adjusted with sodium chloride to 280–320 mOsm/kg. Bacterial endotoxin acceptance is based on the maximum dose; for small-volume parenterals administered to poultry or swine, an endotoxin limit of ≤0.5 EU/mL is commonly applied using USP <85>. Sterility is confirmed by membrane filtration per USP <71>. Particulate matter is controlled per USP <788>. The finished injection is filled into amber glass vials under nitrogen. Terminal autoclaving above 115°C is not recommended unless liquid chromatography shows baicalin degradation below the identification threshold; published thermal degradation kinetics for this specific extract are limited.

Formulation incompatibility exists with calcium- or magnesium-containing diluents because baicalin and related flavonoids can form insoluble metal chelates. The injection should therefore be compounded with sodium chloride or dextrose only.

Capsule Fill Parameters with Adsorbed Extract on Microcrystalline Cellulose

For capsule filling, the oral solution concentrate is converted to a free-flowing powder by adsorption. The extract solution is sprayed onto microcrystalline cellulose in a planetary mixer at a ratio of 1.0 part extract solids to 1.5–2.0 parts microcrystalline cellulose. The wet mass is dried at 45–50°C to moisture ≤3.0%. The dried adsorbate is then blended with lactose monohydrate to achieve a final fill formulation of 25–45 wt% extract solids, 40–55 wt% microcrystalline cellulose, 2–4 wt% sodium starch glycolate, 0.5–1.0 wt% colloidal silicon dioxide, and 0.5–1.0 wt% magnesium stearate. The colloidal silicon dioxide is pre-blended with the extract adsorbate for 5 min before adding the remaining excipients.

Flow properties are controlled by angle of repose, Carr index, and bulk density. The angle of repose should be 25–30°, the Carr index 15–20%, and the bulk density 0.45–0.60 g/mL. On an automatic dosator encapsulator running at 60,000 capsules/h, the fill weight variation should not exceed 3.0% RSD for size 0 capsules. Hard gelatin capsules are less preferred than HPMC capsules when the extract is hygroscopic; HPMC shells reduce cross-linking risk. Disintegration is tested per USP <701> and dissolution in 0.1 M hydrochloric acid per USP <711>.

The terminal capsule is typically filled to 250 mg or 500 mg total mass for companion-animal dosing. Capsules should be packaged in HDPE bottles with a desiccant canister if ambient moisture exceeds 60% RH. The adsorption step must be revalidated when the supplier changes the extract total solids by more than 2% absolute, because the carrier ratio changes and the fill weight must be recalculated.

In feed top-dressing and drinking-water powders, the extract is spray-dried onto maltodextrin with a dextrose equivalent of 12–18 and colloidal silicon dioxide. A typical dry intermediate contains 1.0 part extract solids, 2.0 parts maltodextrin, and 0.5 part colloidal silicon dioxide. Fluid-bed top-spray drying is performed at inlet air 60°C, product temperature 35–40°C, atomising pressure 1.5 bar, and spray rate 80–120 g/min per kg batch. The resulting powder is controlled to moisture ≤3.0%, bulk density 0.45–0.60 g/mL, and D50 180–250 µm. If the exhaust humidity exceeds 60% RH, drying capacity falls and the spray rate is reduced by 20%.

Batch-to-batch variation in extract solids must be measured before dilution. The extract solution should be assayed by HPLC for baicalin using ChP 2020 General Chapter 0512. If baicalin content varies by more than 5% relative from the supplier certificate, the spray-drying feed ratio is recalculated to maintain the dry powder marker content. The final powder is filled into 100 g or 500 g sachets. Microbial quality is tested per USP <61> and USP <62>. The powder should be used within 24 h after reconstitution in drinking water unless a stability study supports a longer in-use period.

Premix Carry and Segregation Control at 0.5% Inclusion

Premix manufacture requires a separate line with contained mixing and validated cleanout. The dried extract powder is blended at 1–5 wt% into a carrier of ground rice hulls or corncob. Vegetable oil is added at 0.5–1.0 wt% as a dust suppressant and binder. Mixing is performed in a horizontal ribbon mixer for 10 min at 20–30 rpm. The premix is discharged by gravity into lined paper bags; pneumatic conveying after mixing is avoided because density differences between extract particles and carrier produce segregation.

Validation of mix uniformity is performed by sampling 10 locations after discharge per ISO 6497:2002. The coefficient of variation for baicalin content should be ≤5.0%. Table 2 lists a typical validation matrix for a production-scale ribbon mixer.

The final feed inclusion rate for baicalin as a marker is normally set by the veterinary prescription. Published monographs for this specific botanical premix are limited; target inclusion should not be extrapolated from human preparations. Typical supportive use in poultry feed requires a baicalin intake that is confirmed by the prescribing veterinarian. Carry-over risk is controlled by cleaning validation with swab and rinse sampling. Cross-contamination acceptance is based on a maximum carry-over of 1% of the lowest therapeutic concentration into the subsequent batch.

Solubility Boundary and pH Drift in Ready-to-Use Veterinary Liquids

Ready-to-use oral liquids are prepared by diluting the concentrated extract with purified water to the target baicalin concentration defined by the marketing authorisation. If no authorised specification is assigned, the receiving site must calculate the dilution from the batch potency assay rather than from a fixed volume ratio. pH is adjusted to 5.0–6.5; below 4.0 precipitation of flavonoid aglycones increases, and above 7.0 oxidative browning accelerates. The solution density is typically 1.02–1.08 g/mL, and the liquid is held at 2–8°C for 24 h to sediment high-molecular-weight polysaccharides.

Preservative selection is constrained by the botanical matrix. Potassium sorbate at 0.1–0.2% w/v and sodium benzoate at 0.1–0.2% w/v are used after pH adjustment to 5.0–5.5. Preservative efficacy is confirmed per USP <51>. High concentrations of non-ionic surfactants are avoided because they can reduce preservative efficacy. The solution is filtered through a 1.0 µm cartridge before filling into 100 mL, 250 mL, or 500 mL amber glass or PET bottles. Storage is at not more than 25°C and protected from light. Freeze-thaw cycling is not recommended because polyphenol precipitation occurs and redissolution is incomplete.

The terminal liquid is administered via drinking water after dilution. Dilution ratios are expressed as millilitres of oral solution per liter of drinking water and are determined by the baicalin marker intake. The solution should be used within 24 h after dilution in drinking water lines unless a stability study demonstrates longer in-use stability. Piping, dosing pumps, and nipple drinkers should be checked for residue build-up because the extract can adhere to biofilm in warm water lines.